SCHEMBL20636667

SCHEMBL20636667

Cc1c(B2OC(C)(C)C(C)(C)O2)cc(C(=O)N[C@H]2COCC[C@@H]2O)c(F)c1C

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 16/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20636646 0.94 CHRM1 (0.43) CHRM1
SCHEMBL20636616 0.86 CHRM1 (0.35) CHRM1
SCHEMBL20636634 0.80 CHRM1 (0.46) CHRM1
SCHEMBL16937028 0.78 CHRM1 (0.61) CHRM1
SCHEMBL20636629 0.76 CHRM1 (0.46) CHRM1
SCHEMBL23698954 0.75 CHRM1 (0.39) CHRM1
SCHEMBL18338850 0.72 CHRM1 (0.42) CHRM1
SCHEMBL20636640 0.71 UCHL1 (0.34) —
SCHEMBL23712085 0.69 CHRM1 (0.36) CHRM1
SCHEMBL23698892 0.69 CHRM1 (0.36) CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3428150-B1 AROMATIC RING COMPOUND HAVING A CHOLINERGIC MUSCARINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR ACTIVITY TAKEDA PHARMACEUTICALS CO (JP) 2023-07-12 — — EP disclosed
US-10548877-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-04 — — US disclosed
US-20190083467-A1 AROMATIC RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-03-21 — — US disclosed
EP-3428150-A1 AROMATIC RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-01-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190083467-A1 AROMATIC RING COMPOUND CHRM1, CHRM2, CHRM4 CHRM1 1/4885
US-10548877-B2 Aromatic ring compound CHRM1, CHRM2, CHRM4 CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback